Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate.

Literature DB >> 24255568

Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate.

Jacopo Giuliani¹, Andrea Bonetti.

Abstract

Entities: Chemical Disease

Year: 2013 PMID： 24255568 PMCID： PMC3828449 DOI： 10.3978/j.issn.1000-9604.2013.10.13

Source DB: PubMed Journal: Chin J Cancer Res ISSN： 1000-9604 Impact factor: 5.087

× No keyword cloud information.

15 in total

Review 1. Occurrence of other malignancies in patients with gastrointestinal stromal tumors.

Authors: Abbas Agaimy; Peter H Wünsch; Leslie H Sobin; Jerzy Lasota; Markku Miettinen
Journal: Semin Diagn Pathol Date: 2006-05 Impact factor: 3.464

2. KIT as a therapeutic target in metastatic melanoma.

Authors: Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal: JAMA Date: 2011-06-08 Impact factor: 56.272

3. ARG tyrosine kinase activity is inhibited by STI571.

Authors: K Okuda; E Weisberg; D G Gilliland; J D Griffin
Journal: Blood Date: 2001-04-15 Impact factor: 22.113

4. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.

Authors: Eduardo A Perez; Alan S Livingstone; Dido Franceschi; Caio Rocha-Lima; David J Lee; Nicole Hodgson; Merce Jorda; Leonidas G Koniaris
Journal: J Am Coll Surg Date: 2006-04 Impact factor: 6.113

5. Synchronous occurrence of epithelial and stromal tumors in the stomach: a report of 6 cases.

Authors: A Maiorana; R Fante; A Maria Cesinaro; R Adriana Fano
Journal: Arch Pathol Lab Med Date: 2000-05 Impact factor: 5.534

6. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors: M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal: Blood Date: 2000-08-01 Impact factor: 22.113

7. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

Authors: Dushyant Verma; Hagop Kantarjian; Sara S Strom; Mary Beth Rios; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal: Blood Date: 2011-08-16 Impact factor: 22.113

8. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.

Authors: Avo Artinyan; Joseph Kim; Perry Soriano; Warren Chow; Smita Bhatia; Joshua D I Ellenhorn
Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254

Review 9. Small gastrointestinal stromal tumor concomitant with early gastric cancer: a case report.

Authors: Ying-Lung Lin; Jeh-En Tzeng; Chang-Kou Wei; Chih-Wen Lin
Journal: World J Gastroenterol Date: 2006-02-07 Impact factor: 5.742

10. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.

Authors: Tatsuo Kanda; Takashi Ishikawa; Seiichi Hirota; Kazuhito Yajima; Shin-ichi Kosugi; Manabu Ohashi; Satoshi Suzuki; Yasuoki Mashima; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal: Jpn J Clin Oncol Date: 2012-04-21 Impact factor: 3.019

4 in total

Review 4. Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer.

Authors: Marcel Sambo
Journal: Cancer Med Date: 2022-10 Impact factor: 4.711